Barclays PLC Has $980,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Barclays PLC increased its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 145.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 79,740 shares of the company’s stock after purchasing an additional 47,239 shares during the quarter. Barclays PLC’s holdings in Stoke Therapeutics were worth $980,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in STOK. Lynx1 Capital Management LP boosted its holdings in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter. Logos Global Management LP bought a new stake in Stoke Therapeutics during the second quarter worth $14,186,000. Marshall Wace LLP raised its position in Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after acquiring an additional 982,451 shares in the last quarter. Finally, RTW Investments LP raised its position in Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $10.80 on Tuesday. Stoke Therapeutics, Inc. has a 52-week low of $4.09 and a 52-week high of $17.58. The business’s fifty day moving average is $12.32 and its 200-day moving average is $13.37. The firm has a market cap of $572.04 million, a price-to-earnings ratio of -5.14 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the transaction, the chief executive officer now directly owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares in the company, valued at $618,913.39. The trade was a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is currently owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.